We have written about jCyte many times on The Stem Cellar. For one reason, they are showing really encouraging results in their treatment for retinitis pigmentosa (RP). And now they have taken an even deeper dive into those results and identified which patients may be most likely to benefit from the therapy. RP is a … Continue reading Identifying the visually impaired patients most likely to benefit from jCyte’s stem cell therapy
Henry Klassen
Meet the people who are changing the future
Kristin MacDonald Every so often you hear a story and your first reaction is “oh, I have to share this with someone, anyone, everyone.” That’s what happened to me the other day. I was talking with Kristin MacDonald, an amazing woman, a fierce patient advocate and someone who took part in a CIRM-funded clinical trial … Continue reading Meet the people who are changing the future
A clear vision for the future
Dr. Henry Klassen and Dr. Jing Yang, founders of jCyte When you have worked with a group of people over many years the relationship becomes more than just a business venture, it becomes personal. That's certainly the case with jCyte, a company founded by Drs. Henry Klassen and Jing Yang, aimed at finding a cure … Continue reading A clear vision for the future
The story behind the book about the Stem Cell Agency
WHY I WROTE “CALIFORNIA CURES” By Don C. Reed It was Wednesday, June 13th, 2018, the launch day for my new book, “CALIFORNIA CURES: How the California Stem Cell Research Program is Fighting Your Incurable Disease!” As I stood in front of the audience of scientists, CIRM staff members, patient advocates, I thought to myself, … Continue reading The story behind the book about the Stem Cell Agency
jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
When the US Congress approved, and President Obama signed into law, the 21st Century Cures Act last year there was guarded optimism that this would help create a more efficient and streamlined, but no less safe, approval process for the most promising stem cell therapies. Even so many people took a wait and see approach, … Continue reading jCyte gets FDA go-ahead for Fast Track review process of Retinitis Pigmentosa stem cell therapy
jCyte starts second phase of stem cell clinical trial targeting vision loss
Studies show that Americans fear losing their vision more than any other sense, such as hearing or speech, and almost as much as they fear cancer, Alzheimer’s and HIV/AIDS. That’s not too surprising. Our eyes are our connection to the world around us. Sever that connection, and the world is a very different place. For … Continue reading jCyte starts second phase of stem cell clinical trial targeting vision loss
California’s stem cell agency rounds up the year with two more big hits
It’s traditional to end the year with a look back at what you hoped to accomplish and an assessment of what you did. By that standard 2016 has been a pretty good year for us at CIRM. Yesterday our governing Board approved funding for two new clinical trials, one to help kidney transplant patients, the … Continue reading California’s stem cell agency rounds up the year with two more big hits
How stem cells are helping change the face of medicine, one pioneering patient at a time
One of the many great pleasures of my job is that I get to meet so many amazing people. I get to know the researchers who are changing the face of medicine, but even more extraordinary are the people who are helping them do it, the patients. Attacking Cancer It’s humbling to meet people like … Continue reading How stem cells are helping change the face of medicine, one pioneering patient at a time
CIRM-funded stem cell trial for retinitis pigmentosa makes progress
A CIRM-funded clinical trial for retinitis pigmentosa (RP), a degenerative eye disease that causes blindness, recently reached its next milestone and announced the completion of its patient enrollment for a phase I/IIa study testing a stem cell derived therapy. This is a major step forward in determining whether this approach is both safe and effective … Continue reading CIRM-funded stem cell trial for retinitis pigmentosa makes progress
CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage
How retinitis pigmentosa erodes normal vision The failure rate for clinical trials is depressingly high. A study from Tufts University in 2010 found that for small molecules – the substances that make up more than 90 percent of the drugs on the market today – the odds of getting from a Phase 1 trial to … Continue reading CIRM-funded stem cell clinical trial for retinitis pigmentosa focuses on next stage